№ files_lp_3_process_7_083684
File format: docx
Character count: 12451
File size: 198 KB
The document is a contractual agreement between A1 Certifier Pty Ltd and its client, outlining the terms and conditions of professional services provided, including fees, associated costs, and responsibilities.
Note:
Year
Subject:
Contractual Terms and Professional Services
Document Type:
Agreement
Organization / Institution:
A1 Certifier Pty Ltd
Author:
A1 Certifier Pty Ltd
Target Audience:
Clients entering into a contractual agreement with A1 Certifier Pty Ltd
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Jurisdiction:
Victoria, Australia
Legislation:
Legal Aid Act 1978 (Vic)
Relevant Act:
Family Violence Protection Act 2008 (Vic)
Issuing body:
Victoria Legal Aid (VLA)
Document type:
Application form
Subject:
Appointment as Individual Certifier on the Family Violence Panel
Eligibility criteria:
Practising certificate, Working with Children Check, panel membership, practice experience
Related panels:
Family Law Panel; Child Protection Panel; Independent Children’s Lawyer Panel
Submission method:
Email to [email protected]
Target audience:
Private legal practitioners in Victoria
Assessment process:
Panel assessor review
Declaration requirement:
Confirmation of truthfulness and authorisation for record checks
Year:
1978
Region / City:
Victoria, Australia
Subject:
Legal Aid Application, Criminal Law
Document Type:
Application Form
Organization:
Victoria Legal Aid (VLA)
Author:
Victoria Legal Aid
Target Audience:
Legal Practitioners
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2018
Region / City:
Australian Capital Territory
Topic:
Administrative Review, Land Development
Document Type:
Legal Decision
Authority / Institution:
ACT Civil and Administrative Tribunal
Author:
Senior Member G Lunney SC, Senior Member R Pegrum
Target Audience:
Legal Professionals, Planners, Developers
Period of Action:
2017-2018
Approval Date:
14 December 2017
Date of Decision:
20 April 2018
Legislation Cited:
ACT Civil and Administrative Tribunal Act 2008 s 68, Planning and Development Act 2007 ss 48, 50, 53, 55, 113, 119, 120, 407
Cases Cited:
Morozow v ACT Planning and Land Authority [2017] ACAT 79
Contextual Description:
A legal decision regarding the approval and conditions for the construction of a single-storey building containing a restaurant and takeaway food shop, including associated works and conditions on land use in the Australian Capital Territory.
Year:
2020
Region / city:
Australia
Topic:
Biosimilar medicine submission
Document type:
Pharmaceutical submission
Organization / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Maxx Pharma Pty Ltd
Target audience:
Healthcare professionals, regulatory bodies
Period of validity:
Ongoing
Approval date:
November 2022
Modification date:
November 2022
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical submission for drug listing
Document Type:
Pharmaceutical submission
Organization:
Janssen-Cilag Pty Ltd
Author:
Not specified
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Not specified
Approval Date:
Not specified
Date of Changes:
March 2025
Note:
Context
Year:
2023
Region / City:
Australia
Theme:
Medicine, Oncology
Document Type:
Submission Report
Organization / Institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
JANSSEN-CILAG PTY LTD
Target Audience:
Healthcare professionals, regulators
Period of Validity:
Ongoing
Approval Date:
28 March 2023
Modification Date:
December 2022
Year:
2025
Region / City:
South Africa
Subject:
Insolvency and liquidation claim procedures
Document Type:
Legal Form
Organ / Institution:
Liquidation Office
Author:
Not specified
Target Audience:
Creditors of the Insolvent Estate
Period of Effect:
From date of sequestration/liquidation
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2023
Region / City:
Australia
Subject:
Chronic migraine, medicinal product submission
Document type:
Submission for PBS listing
Organization:
Novartis Pharmaceuticals Australia Pty. Limited
Author:
Not specified
Target audience:
Health professionals, pharmaceutical regulatory bodies
Period of validity:
Not specified
Date of approval:
2 July 2018
Date of amendments:
November 2023
Year:
2024
Region / City:
Australia
Topic:
Medicinal Product Registration
Document Type:
Submission Report
Agency:
Therapeutic Goods Administration (TGA)
Author:
GlaxoSmithKline Australia
Target Audience:
Medical Practitioners
Treatment Phase:
Initial Treatment
Indication:
Myelofibrosis, including primary, post-polycythaemia vera, and post-essential thrombocythaemia myelofibrosis
Approval Status:
Pending
Date of Submission:
May 2024
Date of Approval:
Not yet approved
Background:
Momelotinib is currently approved in the UK, US, Japan, and the EU.
Description:
Clinical submission for listing momelotinib under the Australian PBS for the treatment of myelofibrosis in patients with moderate to severe anaemia.
Year:
2023
Region / city:
Australia
Theme:
Pharmaceutical submission
Document type:
Pharmaceutical submission
Organization / institution:
Pfizer Australia Pty Ltd
Author:
Not specified
Target audience:
Medical practitioners, nurse practitioners
Effective period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Context:
Pharmaceutical submission requesting the inclusion of a new formulation of methotrexate under the General Schedule of the PBS for Australia, with changes in packaging and excipient composition.
Year:
2023
Region / city:
Australia
Topic:
Vedolizumab submission for chronic pouchitis treatment
Document type:
Submission for listing of medicinal product
Agency:
Therapeutic Goods Administration (TGA)
Author:
Takeda Pharmaceuticals Australia Pty. Ltd.
Target audience:
Healthcare professionals, regulatory authorities
Effective period:
From 29 June 2023
Approval date:
29 June 2023
Modification date:
N/A
Year:
2022
Region / City:
Australia
Topic:
Medical treatment approval and submission for pembrolizumab and lenvatinib
Document type:
Submission for drug listing
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC), Therapeutic Goods Administration (TGA)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Medical professionals, health regulators
Period of validity:
2022 onward
Approval date:
August 10, 2021
Amendment date:
Not specified
Year:
2023
Region / city:
Australia
Theme:
Oncology, Chronic Lymphocytic Leukaemia
Document Type:
Resubmission Report
Organization:
AstraZeneca Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, healthcare policymakers
Period of validity:
Not specified
Approval Date:
November 2019
Date of Changes:
December 2022
Year:
2022
Region / City:
Johannesburg
Subject:
Legal dispute regarding eviction and payment failure
Document Type:
Judgment
Organ / Institution:
High Court of South Africa
Author:
Bester AJ
Target Audience:
Legal professionals, parties involved in the case
Effective Period:
2022-2023
Approval Date:
2022
Date of Changes:
None
Year:
2020
Region / City:
Australia
Topic:
Pharmaceutical Benefits Scheme (PBS) listing
Document Type:
Committee Submission
Agency:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Committee Secretariat
Target Audience:
Healthcare professionals, PBAC members
Period of Effect:
From May 13, 2020
Approval Date:
May 13, 2020
Modification Date:
Not specified
Year:
2023
Region / City:
Australia
Theme:
Oncology, Pharmaceutical
Document Type:
Submission
Organization / Institution:
Merck Sharp & Dohme (Australia) Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, policymakers
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2018
Region / City:
Australia
Topic:
Pharmaceutical Submission, Cancer Treatment
Document Type:
Submission
Organization / Institution:
Takeda Pharmaceuticals Australia Pty Ltd
Author:
Takeda Pharmaceuticals Australia Pty Ltd
Target Audience:
Healthcare professionals, PBAC
Period of Validity:
Ongoing
Approval Date:
23 May 2018
Date of Amendments:
Not specified
Year:
2019
Region / City:
United States
Topic:
Immigration Services
Document Type:
Instruction Manual
Organization:
U.S. Citizenship and Immigration Services (USCIS)
Author:
U.S. Citizenship and Immigration Services
Target Audience:
Individuals applying for immigration benefits
Effective Period:
Ongoing, with periodic updates
Approval Date:
10/15/2019
Date of Changes:
10/15/2019
Year:
2026
Region / City:
California
Subject:
Physician Fee Schedule
Document Type:
Regulatory Document
Organization:
California Department of Industrial Relations
Author:
Administrative Director
Target Audience:
Healthcare Providers, Medical Practitioners, Legal and Compliance Professionals
Period of Action:
From January 1, 2014
Approval Date:
Not specified
Date of Changes:
Effective from March 1, 2017, with further amendments expected until February 15, 2024.
Year:
2025
Region / City:
California
Subject:
Medical Fee Schedule
Document Type:
Regulation
Authority:
Administrative Director – Administrative Rules
Author:
California Labor Code
Target Audience:
Physicians, Non-Physician Practitioners, Healthcare Providers
Effective Period:
2025-2026
Approval Date:
2/1/2025
Revision Date:
1/15/2026